Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Apadamtase alfa - Takeda

Next Previous
Drug Profile

Apadamtase alfa - Takeda

Alternative Names: ADAMTS13, recombinant-krhn - Takeda; ADZYNMA; BAX-930; Cinaxadamtase alfa; rADAMTS-13; Recombinant ADAMTS13; Recombinant-A disintegrin and mellatoproteinase with thrombospondin type-1 motifs-13; SHP-655; TAK 755

Latest Information Update: 31 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kaketsuken
  • Developer Takeda
  • Class Antithrombotics; Disintegrins; Enzymes; Metalloproteases; Recombinant proteins
  • Mechanism of Action ADAMTS13 protein replacements; Enzyme replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thrombotic thrombocytopenic purpura; Sickle cell anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Thrombotic thrombocytopenic purpura
  • Phase I Vaso-occlusive crisis

Most Recent Events

  • 07 Dec 2024 Pooled adverse events, pharmacokinetics and efficacy data from phase III and IIIb trials in Thrombotic thrombocytopenic purpura (cTTP) presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)
  • 07 Aug 2024 Registered for Thrombotic thrombocytopenic purpura (In adolescents, In children, In the elderly, In adults) in Iceland (IV)
  • 07 Aug 2024 Registered for Thrombotic thrombocytopenic purpura (In adolescents, In children, In the elderly, In adults) in Liechtenstein (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top